Investing in biotech isn’t easy. Ask David Brennan, the outgoing CEO of AstraZeneca (LSE: AZN.L - news) , who lost his job because the pharmaceutical giant has been too slow replacing its drug pipeline. If it’s difficult for industry insiders, it’s nigh-on impossible for the layman. I, for one, am totally bamboozled by talk of ologies and therapies.
